<font color="blue">Salmeterol_4</font> <font color="blue">plus_4</font> <font color="blue">fluticasone_4</font> <font color="blue">propionate_4</font> versus <font color="blue">fluticasone_4</font> <font color="blue">propionate_4</font> <font color="blue">plus_4</font> <font color="blue">montelukast_4</font> <font color="blue">:_4</font> a randomised controlled trial investigating the effects on airway inflammation in asthma . 
<br>
<br> BACKGROUND Few studies have compared treatment strategies in patients with asthma poorly controlled on low dose inhaled corticosteroids , and little is known about the effects of different treatments on airway inflammation . In this double - blind , placebo - controlled , parallel group study , we compared the <font color="blue">effects_1</font> <font color="blue">of_1</font> <font color="blue">salmeterol_5</font> <font color="blue">plus_5</font> <font color="blue">fluticasone_5</font> <font color="blue">propionate_5</font> <font color="blue">(_5</font> <font color="blue">FP_5</font> <font color="blue">)_5</font> <font color="blue">(_5</font> <font color="blue">Seretide_5</font> <font color="blue">;_5</font> <font color="blue">SFC_5</font> <font color="blue">)_5</font> <font color="blue">and_1</font> <font color="blue">FP_5</font> <font color="blue">plus_5</font> <font color="blue">montelukast_5</font> <font color="blue">(_5</font> <font color="blue">FP_5</font> <font color="blue">/_5</font> <font color="blue">M_5</font> <font color="blue">)_5</font> <font color="blue">on_1</font> <font color="blue">sputum_1</font> <font color="blue">inflammatory_1</font> <font color="blue">markers_1</font> <font color="blue">,_1</font> <font color="blue">airway_1</font> <font color="blue">responsiveness_1</font> <font color="blue">,_1</font> <font color="blue">lung_1</font> <font color="blue">function_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">symptoms_1</font> <font color="blue">in_1</font> <font color="blue">adult_1</font> <font color="blue">asthmatics_1</font> <font color="blue">._1</font> 
<br> METHODS Sixty - six subjects were <font color="blue">randomised_2</font> <font color="blue">to_2</font> <font color="blue">SFC_4</font> <font color="blue">or_3</font> <font color="blue">FP_4</font> <font color="blue">/_4</font> <font color="blue">M_4</font> <font color="blue">for_2</font> <font color="blue">12_2</font> <font color="blue">weeks_2</font> <font color="blue">._2</font> The primary outcome was changes in <font color="blue">neutrophil_1</font> <font color="blue">,_1</font> <font color="blue">eosinophil_1</font> <font color="blue">,_1</font> <font color="blue">macrophage_1</font> <font color="blue">,_1</font> <font color="blue">lymphocyte_1</font> <font color="blue">,_1</font> <font color="blue">and_1</font> <font color="blue">epithelial_1</font> <font color="blue">cell_1</font> <font color="blue">levels_1</font> <font color="blue">in_1</font> <font color="blue">induced_1</font> <font color="blue">sputum_1</font> <font color="blue">._1</font> Additional outcomes included the change in other sputum markers of airway inflammation , airway responsiveness , symptom control , and lung function . 
<br> RESULTS <font color="blue">Both_1</font> <font color="blue">treatments_1</font> had no significant effect on induced sputum inflammatory cells , although there was a trend for a reduction in sputum eosinophils . Both treatments significantly improved airway responsiveness , whereas <font color="blue">SFC_4</font> generally led to greater improvements in symptom control and lung function than <font color="blue">FP_4</font> <font color="blue">/_4</font> <font color="blue">M._4</font> <font color="blue">FP_4</font> <font color="blue">/_4</font> <font color="blue">M_4</font> led to significantly greater reductions in sputum cysteinyl leukotrienes than <font color="blue">SFC_4</font> ( treatment ratio 1.80 ; 95% CI 1.09 , 2.94 ) . 
<br> CONCLUSION <font color="blue">Both_1</font> <font color="blue">treatments_1</font> led to similar control of eosinophilic airway inflammation , although PEF and symptom control were better with <font color="blue">SFC_4</font> <font color="blue">._4</font> STUDY NUMBER : SAM40030 ( SOLTA ) .